These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 25192198

  • 1. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
    Wu CP, Hsiao SH, Luo SY, Tuo WC, Su CY, Li YQ, Huang YH, Hsieh CH.
    Mol Pharm; 2014 Oct 06; 11(10):3727-36. PubMed ID: 25192198
    [Abstract] [Full Text] [Related]

  • 2. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Wu CP, Hsieh CH, Hsiao SH, Luo SY, Su CY, Li YQ, Huang YH, Huang CW, Hsu SC.
    Mol Pharm; 2015 Nov 02; 12(11):3885-95. PubMed ID: 26412161
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
    Chou YS, Yen CC, Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH, Liu CL.
    Int J Oncol; 2016 Mar 02; 48(3):1187-94. PubMed ID: 26794530
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.
    Oncotarget; 2017 Jan 24; 8(4):6730-6741. PubMed ID: 28036269
    [Abstract] [Full Text] [Related]

  • 6. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.
    Clin Exp Ophthalmol; 2017 Apr 24; 45(3):288-296. PubMed ID: 27647547
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.
    Leukemia; 2009 Sep 24; 23(9):1564-76. PubMed ID: 19421227
    [Abstract] [Full Text] [Related]

  • 13. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.
    Cell Cycle; 2011 Apr 15; 10(8):1303-11. PubMed ID: 21436619
    [Abstract] [Full Text] [Related]

  • 14. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
    Brassesco MS, Pezuk JA, Salomão KB, Roberto GM, Scrideli CA, Tone LG.
    Anticancer Agents Med Chem; 2018 Apr 15; 18(9):1252-1257. PubMed ID: 29493466
    [Abstract] [Full Text] [Related]

  • 15. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA, Brassesco MS, Ramos PMM, Scrideli CA, Tone LG.
    Anticancer Agents Med Chem; 2017 Apr 15; 17(9):1278-1291. PubMed ID: 28270075
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
    Giordano A, Liu Y, Armeson K, Park Y, Ridinger M, Erlander M, Reuben J, Britten C, Kappler C, Yeh E, Ethier S.
    PLoS One; 2019 Apr 15; 14(11):e0224420. PubMed ID: 31751384
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
    Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):102-5. PubMed ID: 18616938
    [Abstract] [Full Text] [Related]

  • 19. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
    Bogado RF, Pezuk JA, de Oliveira HF, Tone LG, Brassesco MS.
    Anticancer Drugs; 2015 Jan 04; 26(1):56-63. PubMed ID: 25089571
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Anticancer Drugs; 2011 Jun 04; 22(5):444-53. PubMed ID: 21399492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.